
Ampyra
Brand for: Dalfampridine er
My Prescription
Payment
Select pharmacy




$36.79
Print or send this coupon to your phone
About Ampyra
Drug Details
Dalfampridine is an oral medication, commonly known by its brand name Ampyra, designed to help improve walking in individuals with multiple sclerosis (MS). This drug functions as a potassium channel blocker, which aids in enhancing nerve conduction. In MS, nerve damage can cause excessive potassium to escape from nerve cells, hindering their function. By blocking these potassium channels, dalfampridine helps improve the conduction of nerve signals. Patients should be aware that side effects may include urinary tract infections, insomnia, and dizziness. It is available both as a brand-name product and a more affordable generic version. Always consult with a healthcare professional before starting any new medication.
Ampyra (Dalfampridine ER) dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 10MG | 60 Tablet Extended Release 12 Hours | $36.79 | $0.61 |
Ampyra FAQs
AMPYRA (dalfampridine) is a medication used to improve walking in adults with multiple sclerosis (MS). It works by blocking potassium channels on nerve cells, which can enhance the conduction of nerve signals in damaged nerves. This can lead to improved walking speed and mobility in individuals with MS.
AMPYRA (dalfampridine) is a medication that helps improve walking in individuals with multiple sclerosis (MS). It works by blocking potassium channels on nerve cells, which can enhance the conduction of nerve signals. This improved nerve signal transmission can lead to better muscle control and coordination, thereby aiding in walking ability.
The cost of AMPYRA can vary based on factors such as insurance coverage, pharmacy pricing, and location. Without insurance, the monthly cost can be quite high, often several thousand dollars. Patients are encouraged to check with their insurance provider for specific coverage details and to explore any available patient assistance programs that may help reduce the cost.
Ampyra (dalfampridine) has been shown to improve walking speed in approximately 35-43% of patients with multiple sclerosis (MS) in clinical trials. It is important to note that individual responses can vary, and not all patients may experience the same level of benefit.
The effectiveness of a medication for improving walking in individuals with multiple sclerosis (MS) can vary based on the individual's specific condition and response to treatment. However, dalfampridine (Ampyra) is a medication that has been specifically approved to improve walking in people with MS. It works by blocking potassium channels on nerve fibers, which can enhance nerve signal conduction. It is important for patients to consult with their healthcare provider to determine the most appropriate treatment for their specific needs.